HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tamio Teramoto Selected Research

Hypercholesterolemia

7/2022Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials.
5/201912-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia　- Data From a Real-World Observational Study of Evolocumab in Japan.
5/2019Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy.
3/2019Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan.
1/2019Long-Term Treatment With Evolocumab Among Japanese Patients　- Final Report of the OSLER Open-Label Extension Studies.
12/2017Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia.
10/2017Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia.
6/2017Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
8/2016Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　- ODYSSEY JAPAN Randomized Controlled Trial.
7/2016Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies).
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tamio Teramoto Research Topics

Disease

31Hypercholesterolemia
07/2022 - 05/2002
24Cardiovascular Diseases (Cardiovascular Disease)
07/2022 - 01/2008
22Dyslipidemias (Dyslipidemia)
10/2021 - 10/2002
16Atherosclerosis
06/2022 - 01/2002
14Hypertension (High Blood Pressure)
01/2019 - 02/2007
12Coronary Disease (Coronary Heart Disease)
01/2019 - 07/2002
10Metabolic Syndrome (Dysmetabolic Syndrome X)
12/2012 - 01/2005
9Hyperlipidemias (Hyperlipidemia)
01/2020 - 01/2002
9Stroke (Strokes)
01/2019 - 01/2008
8Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
01/2020 - 01/2016
6Diabetes Mellitus
03/2019 - 10/2008
6Coronary Artery Disease (Coronary Atherosclerosis)
05/2012 - 07/2002
5Type 2 Diabetes Mellitus (MODY)
06/2014 - 10/2002
4Hemorrhage
06/2019 - 03/2010
4Myocardial Infarction
01/2019 - 01/2009
3Body Weight (Weight, Body)
12/2019 - 01/2013
3Myalgia
08/2015 - 11/2011
3Chronic Renal Insufficiency
11/2011 - 06/2010
3Cerebral Infarction
02/2009 - 10/2006
2Hypertriglyceridemia
06/2022 - 11/2012
2Intracranial Hemorrhages (Intracranial Hemorrhage)
06/2019 - 01/2016
2Obesity
02/2018 - 09/2009
2Ischemic Stroke
01/2016 - 01/2016
2Transient Ischemic Attack
01/2016 - 12/2014
2Atherosclerotic Plaque (Atheroma)
05/2014 - 04/2008
1Rheumatoid Arthritis
12/2021
1Inborn Genetic Diseases (Disease, Hereditary)
01/2020
1Gastrointestinal Hemorrhage (Hematochezia)
06/2019
1Cerebral Hemorrhage
06/2019
1Homozygous Familial Hypercholesterolemia
05/2019
1Rhabdomyolysis
05/2019
1Injection Site Reaction
03/2019
1Nasopharyngitis
03/2019
1Back Pain (Backache)
03/2019
1Hemorrhagic Stroke
01/2019
1Neoplasms (Cancer)
04/2018
1Thrombosis (Thrombus)
04/2018
1Fatty Liver
02/2018
1Inflammation (Inflammations)
02/2018
1Metabolic Diseases (Metabolic Disease)
02/2018
1Acute Coronary Syndrome
01/2016
1Peripheral Arterial Disease
01/2016
1Drug-Related Side Effects and Adverse Reactions
08/2015

Drug/Important Bio-Agent (IBA)

35oxidized low density lipoproteinIBA
07/2022 - 05/2002
24LipidsIBA
10/2021 - 01/2002
20Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
06/2022 - 10/2002
20LDL CholesterolIBA
10/2021 - 01/2002
16CholesterolIBA
06/2022 - 01/2002
14HDL CholesterolIBA
01/2015 - 09/2002
14Pravastatin (Pravachol)FDA LinkGeneric
01/2014 - 06/2002
8pitavastatin (itavastatin)FDA Link
08/2015 - 01/2002
7Atorvastatin (Lipitor)FDA Link
01/2019 - 02/2012
7Triglycerides (Triacylglycerol)IBA
01/2013 - 07/2002
6Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
06/2019 - 03/2010
6Lipoproteins (Lipoprotein)IBA
02/2009 - 10/2002
5alirocumabIBA
03/2019 - 01/2016
5Ezetimibe (Zetia)FDA Link
12/2017 - 02/2012
5Cholesterol Ester Transfer ProteinsIBA
12/2017 - 09/2013
5Glucose (Dextrose)FDA LinkGeneric
10/2008 - 08/2006
4BezafibrateIBA
06/2017 - 11/2005
3evolocumabIBA
07/2022 - 01/2014
3HDL LipoproteinsIBA
06/2022 - 07/2002
3N- acetyl- S- (alpha- methyl- 4- (2- methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl esterIBA
04/2018 - 12/2014
3evacetrapibIBA
12/2017 - 06/2014
3anacetrapibIBA
01/2017 - 09/2013
3Antihypertensive Agents (Antihypertensives)IBA
02/2016 - 01/2014
3olmesartanIBA
02/2016 - 11/2008
3LDL Lipoproteins (beta Lipoproteins)IBA
01/2015 - 10/2002
3Proteins (Proteins, Gene)FDA Link
01/2013 - 11/2005
2Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
06/2022 - 01/2020
2EstersIBA
06/2022 - 01/2020
2Fenofibrate (CiL)FDA LinkGeneric
06/2017 - 11/2013
2Pharmaceutical PreparationsIBA
01/2017 - 05/2011
2SodiumIBA
01/2014 - 08/2011
2Creatine Kinase (Creatine Phosphokinase)IBA
11/2013 - 11/2011
2Indicators and Reagents (Reagents)IBA
06/2013 - 11/2012
2Olmesartan Medoxomil (Votum)FDA Link
12/2012 - 11/2008
2SaltsIBA
12/2012 - 01/2011
2Fatty Acids (Saturated Fatty Acids)IBA
01/2011 - 12/2008
2TabletsIBA
06/2010 - 10/2009
2Lipoprotein(a)IBA
09/2009 - 07/2002
2Chylomicron RemnantsIBA
08/2009 - 01/2009
2Apolipoprotein B-48IBA
08/2009 - 04/2008
2PlasmalogensIBA
06/2008 - 02/2007
23-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)IBA
10/2006 - 10/2002
1AntioxidantsIBA
06/2022
1Abatacept (Orencia)FDA Link
12/2021
1bococizumabIBA
12/2019
1Monoclonal AntibodiesIBA
05/2019
1Proprotein Convertase 9IBA
05/2019
1N 556IBA
01/2019
1Phytosterols (Plant Sterols)IBA
02/2018
1gamma-sitosterol (beta-sitosterol)IBA
02/2018
1Cytochrome P-450 CYP2C9IBA
08/2015
1Hemoglobins (Hemoglobin)IBA
01/2015
1darapladibIBA
05/2014

Therapy/Procedure

18Therapeutics
06/2019 - 03/2005
3Secondary Prevention
01/2018 - 11/2011
3Drug Therapy (Chemotherapy)
01/2016 - 01/2011
2Diet Therapy (Therapy, Diet)
07/2020 - 06/2017